# Evolution and contemporary landscape of neonatal hyperbilirubinemia management guidelines: a narrative review

**Authors:** Yaxin Zhang, Yaowen Zhang, Qin Huang, Shuhua Yi, Xiaoqing Guan, Hongyu Li, Jun He

PMC · DOI: 10.3389/fped.2026.1745769 · Frontiers in Pediatrics · 2026-02-06

## TL;DR

This paper reviews global guidelines for managing neonatal jaundice, highlighting differences in care between high-income and low-income countries and suggesting ways to improve equitable treatment.

## Contribution

The paper introduces a 2025 Chinese guideline as a scalable model for low- and middle-income countries.

## Key findings

- Universal principles like early screening and phototherapy are widely endorsed but inconsistently implemented.
- Disparities in neonatal hyperbilirubinemia management exist between high-income and low-income countries.
- The 2025 Chinese guideline offers a model combining risk-stratified screening and local nomograms for LMICs.

## Abstract

Neonatal hyperbilirubinemia, affecting over 60% of term and 80% of preterm infants globally, remains a significant public health challenge due to the persistent risk of kernicterus despite effective management strategies. This narrative review summarizes global clinical practice guidelines to describe the evolution and current landscape of management, highlighting the disparity between evidence-based consensus and local adaptation. While universal principles such as early hyperbilirubinemia screening, phototherapy as the first-line treatment, and post-discharge follow-up are widely endorsed, substantial disparities exist in implementation—particularly between high-income countries and low- and middle-income countries (LMICs)—driven by differences in healthcare resources, sociocultural perceptions, and technological access. The 2025 Chinese guideline is an integrated model combining risk-stratified screening, locally derived hour-specific nomograms, online follow-up, and family engagement, offering a scalable framework for LMICs. Looking ahead, global harmonization may require a dual-layered guideline structure, affordable technology dissemination, culturally adapted family support systems, and inclusion of hyperbilirubinemia metrics in national health performance evaluations to achieve equitable and effective care worldwide.

## Linked entities

- **Diseases:** kernicterus (MONDO:0018477)

## Full-text entities

- **Genes:** ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) [NCBI Gene 28] {aka A3GALNT, A3GALT1, GTA, GTB, NAGAT}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}
- **Diseases:** HL (MESH:C538324), skin pigmentation (MESH:D010859), maternal-infant blood group incompatibility (MESH:D063766), neurotoxicity (MESH:D020258), bilirubin (MESH:D007647), jaundice (MESH:D007565), Neonatal Hyperbilirubinemia (MESH:D051556), ABO hemolysis (MESH:D006461), metabolic disorders (MESH:D008659), neurologic dysfunction (MESH:D009461), hyperthermia (MESH:D005334), breast milk (MESH:D061325), altered consciousness (MESH:D003244), neonatal jaundice (MESH:D007567), skin discoloration (MESH:D014075), neurologic injury (MESH:D020196), encephalopathy (MESH:D001927), G6PD deficiency (MESH:D005955), lethargy (MESH:D053609), asphyxia (MESH:D001237), infections (MESH:D007239), preterm infants (MESH:D047928), prematurity (MESH:C536271), neurodevelopmental impairment (MESH:D009422), sepsis (MESH:D018805), hyperbilirubinemia (MESH:D006932)
- **Chemicals:** TB (MESH:D001663), Phenobarbital (MESH:D010634), TSB (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920545/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920545/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920545/full.md

---
Source: https://tomesphere.com/paper/PMC12920545